screen_shot_2014-02-21_at_10

New head of Biosimilars for Merck KGaA

pharmafile | February 21, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Merck KGaA, biosimilars, simon sturge 

Simon Sturge is joining Merck KGaA from Boehringer Ingelheim in order to head its Biosimilars unit.

In his new role at the German firm Sturge will report to board member Stefan Oschmann and succeeds Thierry Hulot, who created the Biosimilars unit and took over responsibility for the Merck Serono division at the end of last year. 

At Boehringer Sturge headed-up its Biopharmaceuticals (including Biosimilars) division, and previously was chief executive of the Dutch biotech firm OctoPlus. 

Advertisement

Prior to that position he acted as chief executive of Vernalis. Sturge also held several roles of increasing seniority from business development, marketing, operations to chief executive at Lonza Biologics, at Celltech Biologics, and at Astra.

Oschmann said: “Simon Sturge is ideally suited to develop our Biosimilars unit and to be among the important players in this field.”

Related Content

Exscientia enters AI drug discovery collaboration with Merck KGaA

Exscientia has announced a new collaboration with Merck KGaA, Darmstadt, Germany, with a focus on …

biogen_austria_238

Samsung Bioepis & Biogen receive positive CHMP opinion for ranibizumab biosimilar

Samsung Bioepis and Biogen have announced that the EMA’s Committee for Medicinal Products for Human …

Biosimilars and Brexit: What’s in store for UK’s biosimilar market?

It’s been 15 years since the first biosimilar entered the market, and the impact of …

The Gateway to Local Adoption Series

Latest content